Clinical trials: Dementia, Senile
Alzheimer Disease
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of…
- Trial name
- NCT04971733
- Testing
- E2814
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Alzheimer Disease, Cognitive Decline
Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease
The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests.
- Conditions
- Alzheimer Disease, Cognitive Decline, Aging
- Trial name
- NCT04800588
- Testing
- California Cognitive Assessment Battery
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Neurobehavioral Systems, Inc.
Preclinical Alzheimer's Disease
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
- Trial name
- SPINOZA (NCT07794670)
- Testing
- Obicetrapib 10 mg
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- NewAmsterdam Pharma
Alzheimer´s Disease
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers…
- Trial name
- NCT01125683
- Testing
- AZD1446, Donepezil
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Mild Cognitive Impairment (MCI), Alzheimer Disease
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT05108922
- Testing
- Donanemab, Aducanumab
- Where
- 31 sites in United States
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Alzheimer´s Disease
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease.
- Trial name
- AMARANTH (NCT02245737)
- Testing
- Lanabecestat
- Where
- 254 sites in United States, Australia and 13 more
- Volunteers
- 2,218 people
- Sponsor
- AstraZeneca
Lymphoma, Solid Malignancy
PET Imaging of Subjects Using 124I-PU-AD
This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.
- Conditions
- Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
- Trial name
- NCT03371420
- Testing
- PU-AD, PET Scan, Blood Draws
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Samus Therapeutics, Inc.
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
This 2-part, open-label study was designed to investigate the safety, tolerability, and efficacy of [18F]MK-6240, a Positron Emission Tomography (PET) imaging agent, for the quantification of neurofibrillary tangle (NFT)…
- Trial name
- NCT02562989
- Testing
- [18F]MK-6240, ~185 MBq, [18F]MK-6240, ~160 MBq
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
- Trial name
- NCT00934050
- Testing
- ELND005 (scyllo-inositol)
- Where
- 38 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- OPKO Health, Inc.
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping
The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Trial name
- EARS (NCT04928690)
- Volunteers
- 140 people
- Sponsor
- Novoic Limited
Alzheimer Disease
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
- Trial name
- INVOKE-2 (NCT04592874)
- Testing
- AL002
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 356 people
- Sponsor
- Alector Inc.
Alzheimer Disease, Healthy
Study GSI-136 in Healthy Young and Healthy Elderly Subjects
This is a first-in-humans study of GSI-136, a drug being developed for the treatment of Alzheimer Disease. The main purpose of this study is to determine whether GSI-136 is safe and tolerable in healthy young and healthy elderly…
- Trial name
- NCT00718731
- Testing
- GSI-136
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
- Trial name
- NCT06653153
- Testing
- Remternetug
- Where
- 262 sites in United States, Australia and 8 more
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects
The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.
- Trial name
- NCT05408780
- Testing
- AC-OLE-01-VA
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Cerecin
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with…
- Trial name
- NCT07780383
- Testing
- BMS-986446
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Nasal Secretion, Alzheimer Disease
Feasibility of a Method for Analysis of Alzheimer´s Disease Specific Proteins in Nasal Secretion
This study is a first in man study investigating the feasibility of the collection, storage, processing and analysis of 4 key biomarkers for the diagnosis of Alzheimer's disease [AD] in nasal secretion.
- Conditions
- Nasal Secretion, Alzheimer Disease, Brain Nose Interface
- Trial name
- NL02 (NCT05791552)
- Testing
- Collection of nasal secretion
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Noselab GmbH
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimer Disease
Neuro RX Gamma - Pivotal Phase
The active Neuro RX Gamma device uses non-invasive near-infrared energy delivered to the brain with the intention to improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT03484143
- Testing
- Active Neuro RX Gamma device
- Where
- 9 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- Vielight Inc.
Alzheimer's Disease
A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
The objective of this trial was to investigate the effect of galantamine (an acetylcholinesterase inhibitor) on heart rate and PR interval (the time it takes for the heart's electrical impulse to get from the atria to the…
- Trial name
- NCT00309725
- Testing
- galantamine
- Volunteers
- 139 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.